History
2026
- Launched the world's first Autoimmune Diagnostics Streamline combining IFA, multiplexing, and CLIA
2025
- Alzheimer's plasma tests — Aβ42/40 and pTau‑181 (CLIA) — approved and launched； Cytokines and antiphospholipid syndrome‑associated autoantibodies (CLIA) approved and launched； Launched FluoroCore — AI‑assisted IFA Classifier, addressing long‑standing industry pain points through AI technology.
2024
- Unveiled PATHVIZON A1 (All-in-one NAT workstation) & PATHVIZON X50 (World’s first dual-mode immunoanalyzer)
2023
- Became the exclusive global manufacturer of Serodia, TPPA, and MYCOII
2021
- Selected as the exclusive brand for the China CDC HIV Reference Lab
2020
- Co-developed the first COVID-19 antibody test kit with Wuhan Institute of Virology
2019
- Launched the world’s first fully automated DLCM platform
- Launched China's X-ray Blood Irradiator
2017
- Developed the unique Digital Liquid Chip Method (DLCM) Multiplexing
2014
- stablished the Molecular Diagnostics platform for infectious diseases
2010
- Achieved 80%+ market share in HIV and Syphilis confirmatory testing
2003
- Formed strategic alliances with global leaders (Fujirebio, Siemens)
1990
- Pioneered early ELISA diagnostic kits for HBV, HIV, and HCV
1989
- Founded as the first subsidiary of Livzon Pharmaceutical Group
丽珠试剂官方
丽珠试剂资讯
粤公网安备 44049002000690号
Technical Support:E-net